Actemra® (tocilizumab) – Updated labeling

- On February 28, 2022, the FDA approved Genentech's intravenous (IV) formulation of Actemra (tocilizumab), for treatment of giant cell arteritis (GCA) in adult patients.
    - Previously, only the subcutaneous (SC) formulation of Actemra was approved for this indication.
- The IV and SC formulations of Actemra are also approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.
- Additionally, the SC formulation of Actemra is approved for systemic sclerosis-associated interstitial lung disease and the IV formulation is approved for cytokine release syndrome.
- Actemra carries a boxed warning for risk of serious infections.
- The recommended IV dose of Actemra for the treatment of GCA is a 60-minute single IV drip infusion of 6 mg/kg every 4 weeks in combination with a tapering course of glucocorticoids.
    - Actemra can be used alone following discontinuation of glucocorticoids. Doses exceeding 600 mg per infusion are not recommended in GCA patients.
    - Refer to the Actemra drug label for dosing for all its other indications.